Ernexa Therapeutics Inc. Contract with Customer, Asset, after Allowance for Credit Loss
Ernexa Therapeutics Inc. (ERNA) had Contract with Customer, Asset, after Allowance for Credit Loss of $0 as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Balance Sheet › Assets
us-gaap:ContractWithCustomerAssetNet · last filed 2026-03-13
- 2025-12-31: Contract with Customer, Asset, after Allowance for Credit Loss $0.00.
- 2024-12-31: Contract with Customer, Asset, after Allowance for Credit Loss $0.00.
- 2023-12-31: Contract with Customer, Asset, after Allowance for Credit Loss $0.00.
- 2022-12-31: Contract with Customer, Asset, after Allowance for Credit Loss $0.00.
| Period end | Contract with Customer, Asset, after Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-13 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-12 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |